Rigel's SYK inhibitor fostamatinib met the primary endpoint in the first of two pivotal Phase III trials in chronic ITP, but yielded a treatment effect in only 18% of the patients. CEO Raul Rodriguez discussed the data in an interview.
Rigel Pharmaceuticals Inc. has produced positive Phase III data with the platelet drug fostamatinib in chronic/persistent immune thrombocytopenia, putting the oral spleen tyrosine kinase (SYK) inhibitor on footing for a potential approval after the company failed to successfully develop the drug in rheumatoid arthritis.
The South San Francisco, California company reported results from the first of two identical trials in Rigel's Phase III FIT...
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Oral RNA splicing modulator has gone into a Phase II/III trial
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
The first twice-yearly option for HIV prevention has been approved by the US Food and Drug Administration in an advance that “brings us closer than ever to ending the HIV epidemic,” said CEO Daniel O’Day.
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.
